TFII.TO -1.7C -0.53MU 0.36CRWD 7.06PANW 5.71SNOW 21.21V -0.68MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

24.94
-0.08 (0.30%)
as of Aug 3, 2026, 5:47:59 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 3, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc (PFE) is currently navigating a challenging landscape post-COVID, grappling with the loss of patent exclusivity on several of its major drugs. Analysts express a mix of cautious optimism and concern about the company's ability to develop new blockbuster drugs to replenish its pipeline. The consensus highlights a generous dividend yield, typically around 6-8%, which appeals to income-focused investors. However, there's significant uncertainty regarding growth, with many experts pointing to the company's recently acquired drugs and strategic focus on obesity and oncology as potential avenues for future success. Overall, while the stock is deemed undervalued based on its low price-to-earnings ratio, the lack of immediate catalysts for growth and dependency on dividends reflect a complex investment landscape.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
DON'T BUY

Pfizer Inc(PFE)

Jan 13, 2010
Loss of their Lipitor patent in 2011 (25% of revenues) is priced into the stock but this is a problem with all Pharma plays. Patent expirations is hugely punitive. (See Top Picks.)
Photo of Gordon ReidGordon ReidUnlock Rating
$19.21

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 23, 2009
(A Top Pick Jan 27/09. Up 17.5%.) The world hated pharmaceutical stocks but started to like them more. All the major pharmas have patents coming off in the next 5 years. This is already built into the price. Companies have all built up big cash reserves.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$18.58

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 15, 2009
Biovail is the only Canadian equivalent. He likes the industry. Concern as patents expire. Market has valued this concern into the price. Continue to generate cash flow. Prefers Merck.
Photo of Ara NalbandianAra Nalbandian
No
Unlock Rating
$18.29

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 16, 2009
US healthcare stocks were ignored until recently. Recently completed its acquisition of Wyeth, which gives them a new product pipeline. 3.7% yield.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$17.94

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 06, 2009
The issue here is Lipitor patents coming off in 2010 and they have to fill the product pipeline with something that is going to be a blockbuster. Question that they can use their cash horde effectively to fill the R&D pipeline, get new products to market and get their profits up. (See Top Picks.)
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$16.96

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 04, 2009
About the 50-day and 200-day moving averages and is continuing to climb. 3.7% dividend and they are due for an increase.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$16.93

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 27, 2009
Big pharmaceutical has 3 major problems. 1) Cost of developing new drugs keeps going up and up. 2) When you do find a new drug there are chances of killing/harming people accidentally. 3) When you do find a new drug that works, the generics come after you.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$17.26

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Oct 22, 2009
(Market Call Minute) Interesting play. They’ve just done a huge deal. Corporations that do huge take-overs usually take a while to swallow the company.
Photo of Benj GallanderBenj GallanderUnlock Rating
$17.56

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Pfizer Inc(PFE)

Oct 15, 2009
A lot of their drugs were coming off patent, which is why they bought Wyeth, which has a strong portfolio of women's healthcare. With this acquisition closing, she would expect a lot of integration savings and cutting of costs. She would like more detail on this.
Photo of Christine PooleChristine PooleUnlock Rating
$17.66

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 13, 2009
Although they have drugs coming off patent over the next few years, they are acquiring wyeth and they have some promising new drugs.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$16.78

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 08, 2009
Pharmaceutical industry has been very much out of favour. Likes the long-term play in pharmaceuticals with the aging population and demographics. Recently bought Wyeth (WYE-N) and expecting a lot of synergies from this. Trades at 8.5X earnings with almost 4% dividends.
Photo of Colin StewartColin Stewart
Owned
Unlock Rating
$16.70

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 11, 2009
Good performer in the last 6 to 7 months. Decent yield. Problem with all major pharma stocks are the products coming off patent requiring new avenues for growth. Acquired Wyeth (WYE-N), which has fewer drugs coming off patent and more coming on line. (Also owns Teva for their generic drugs.)
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$16.25

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 10, 2009
This will depend on what the US president comes up with on a healthcare plan. Until that is resolved all the drug stocks will be under pressure.
Photo of Peter BriegerPeter Brieger
No
Unlock Rating
$16.34

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 04, 2009
Largest drug company globally. Very strong number of products but along with most of the big pharmaceutical companies there are a large number of drugs that come off patent. About 25% of their earnings comes from one drug, Lipitor and when it comes off patent it will have a big effect on their earnings. There are better places to be.
Photo of Andrew Guy, CFAAndrew Guy, CFAUnlock Rating
$16.39

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 25, 2009
This is not the one to bet on in this sector. Very cheap, up for a reason. Drug pipeline is not impressive. Have patent issues. (See Top Picks.)
Photo of Karl BergerKarl Berger
No
Unlock Rating
$16.80

Stock price when the opinion was issued

$24.91

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
Showing 466 to 480 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG -2.15$146.54
SLB -1.22$48.37
SHEL -0.92$91.06
AAPL -4.25$304.66
AMZN 12.75$284.33

Today's Top Picks

TFII.TO -1.7$13.38
C -0.53$131.92
MU 0.36$823.39
CRWD 7.06$197.92
PANW 5.71$337.54

Popular Articles

Latest Sell Signals

AAPL -4.25$304.66
AAPL -4.25$304.66
AAPL -4.25$304.66
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like